A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

BACKGROUND: In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauman, Julie E, Eaton, Keith D, Wallace, Sarah G, Carr, Laurie L, Lee, Sang-Joon, Jones, Dennie V, Arias-Pulido, Hugo, Cerilli, Lisa A, Martins, Renato G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517479/
https://www.ncbi.nlm.nih.gov/pubmed/23033932
http://dx.doi.org/10.1186/1471-2407-12-449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517479/
https://www.ncbi.nlm.nih.gov/pubmed/23033932
http://dx.doi.org/10.1186/1471-2407-12-449

Ejemplares similares